Trials / Recruiting
RecruitingNCT07380334
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
An Open Label, Multicenter Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 Injection in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, open label, dose exploration/efficacy extension Phase I clinical trial aimed at evaluating the safety, tolerability, pharmacokinetics and efficacy of SHR-1049 injection in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1049 Injection | SHR-1049 injection. |
Timeline
- Start date
- 2026-03-12
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
- First posted
- 2026-02-02
- Last updated
- 2026-04-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07380334. Inclusion in this directory is not an endorsement.